OSARI, an Open-Source Anticipated Response Inhibition Task

Jason L. He; Rebecca J. Hirst; Rohan Puri; James Coxon; Winston Byblow; Mark Hinder; Patrick Skippen; Dora Matzke; Andrew Heathcote; Corey G. Wadsley; Tim Silk; Christian Hyde; Dinisha Parmar; Ernest Pedapati; Donald L. Gilbert; David A. Huddleston; Stewart Mostofsky; Inge Leunissen; Hayley J. MacDonald; Nahian S. Chowdhury; Matthew Gretton; Tess Nikitenko; Bram Zandbelt; Luke Strickland; Nicolaas A.J. Puts

doi:10.3758/s13428-021-01680-9

OSARI, an Open-Source Anticipated Response Inhibition Task

Jason L. He, Rebecca J. Hirst, Rohan Puri, James Coxon, Winston Byblow, Mark Hinder, Patrick Skippen, Dora Matzke, Andrew Heathcote, Corey G. Wadsley, Tim Silk, Christian Hyde, Dinisha Parmar, Ernest Pedapati, Donald L. Gilbert, David A. Huddleston, Stewart Mostofsky, Inge Leunissen, Hayley J. MacDonald, Nahian S. ChowdhuryMatthew Gretton, Tess Nikitenko, Bram Zandbelt, Luke Strickland, Nicolaas A.J. Puts

Research output: Contribution to journal › Article › peer-review

Abstract

The stop-signal paradigm has become ubiquitous in investigations of inhibitory control. Tasks inspired by the paradigm, referred to as stop-signal tasks, require participants to make responses on go trials and to inhibit those responses when presented with a stop-signal on stop trials. Currently, the most popular version of the stop-signal task is the ‘choice-reaction’ variant, where participants make choice responses, but must inhibit those responses when presented with a stop-signal. An alternative to the choice-reaction variant of the stop-signal task is the ‘anticipated response inhibition’ task. In anticipated response inhibition tasks, participants are required to make a planned response that coincides with a predictably timed event (such as lifting a finger from a computer key to stop a filling bar at a predefined target). Anticipated response inhibition tasks have some advantages over the more traditional choice-reaction stop-signal tasks and are becoming increasingly popular. However, currently, there are no openly available versions of the anticipated response inhibition task, limiting potential uptake. Here, we present an open-source, free, and ready-to-use version of the anticipated response inhibition task, which we refer to as the OSARI (the Open-Source Anticipated Response Inhibition) task.

Original language	English (US)
Pages (from-to)	1530-1540
Number of pages	11
Journal	Behavior Research Methods
Volume	54
Issue number	3
DOIs	https://doi.org/10.3758/s13428-021-01680-9
State	Published - Jun 2022
Externally published	Yes

Keywords

Behavioral Inhibition
Inhibition
Stopping
anticipation
executive functioning
opensource
stop-signal task

ASJC Scopus subject areas

Experimental and Cognitive Psychology
Developmental and Educational Psychology
Arts and Humanities (miscellaneous)
Psychology (miscellaneous)
Psychology(all)

Access to Document

10.3758/s13428-021-01680-9

Cite this

He, J. L., Hirst, R. J., Puri, R., Coxon, J., Byblow, W., Hinder, M., Skippen, P., Matzke, D., Heathcote, A., Wadsley, C. G., Silk, T., Hyde, C., Parmar, D., Pedapati, E., Gilbert, D. L., Huddleston, D. A., Mostofsky, S., Leunissen, I., MacDonald, H. J., ... Puts, N. A. J. (2022). OSARI, an Open-Source Anticipated Response Inhibition Task. Behavior Research Methods, 54(3), 1530-1540. https://doi.org/10.3758/s13428-021-01680-9

He, JL, Hirst, RJ, Puri, R, Coxon, J, Byblow, W, Hinder, M, Skippen, P, Matzke, D, Heathcote, A, Wadsley, CG, Silk, T, Hyde, C, Parmar, D, Pedapati, E, Gilbert, DL, Huddleston, DA, Mostofsky, S, Leunissen, I, MacDonald, HJ, Chowdhury, NS, Gretton, M, Nikitenko, T, Zandbelt, B, Strickland, L & Puts, NAJ 2022, 'OSARI, an Open-Source Anticipated Response Inhibition Task', Behavior Research Methods, vol. 54, no. 3, pp. 1530-1540. https://doi.org/10.3758/s13428-021-01680-9

@article{7fc4c675acf64440ae93b9aef1b270ca,

title = "OSARI, an Open-Source Anticipated Response Inhibition Task",

abstract = "The stop-signal paradigm has become ubiquitous in investigations of inhibitory control. Tasks inspired by the paradigm, referred to as stop-signal tasks, require participants to make responses on go trials and to inhibit those responses when presented with a stop-signal on stop trials. Currently, the most popular version of the stop-signal task is the {\textquoteleft}choice-reaction{\textquoteright} variant, where participants make choice responses, but must inhibit those responses when presented with a stop-signal. An alternative to the choice-reaction variant of the stop-signal task is the {\textquoteleft}anticipated response inhibition{\textquoteright} task. In anticipated response inhibition tasks, participants are required to make a planned response that coincides with a predictably timed event (such as lifting a finger from a computer key to stop a filling bar at a predefined target). Anticipated response inhibition tasks have some advantages over the more traditional choice-reaction stop-signal tasks and are becoming increasingly popular. However, currently, there are no openly available versions of the anticipated response inhibition task, limiting potential uptake. Here, we present an open-source, free, and ready-to-use version of the anticipated response inhibition task, which we refer to as the OSARI (the Open-Source Anticipated Response Inhibition) task.",

keywords = "Behavioral Inhibition, Inhibition, Stopping, anticipation, executive functioning, opensource, stop-signal task",

author = "He, {Jason L.} and Hirst, {Rebecca J.} and Rohan Puri and James Coxon and Winston Byblow and Mark Hinder and Patrick Skippen and Dora Matzke and Andrew Heathcote and Wadsley, {Corey G.} and Tim Silk and Christian Hyde and Dinisha Parmar and Ernest Pedapati and Gilbert, {Donald L.} and Huddleston, {David A.} and Stewart Mostofsky and Inge Leunissen and MacDonald, {Hayley J.} and Chowdhury, {Nahian S.} and Matthew Gretton and Tess Nikitenko and Bram Zandbelt and Luke Strickland and Puts, {Nicolaas A.J.}",

note = "Funding Information: JLH and NAP received salary support from the Nancy Lurie Marks foundation. RP and DP were supported through an Australian Government Research Training Program stipend. MRH was supported by the Australian Research Council (FT150100406, DP200101696). JPC is supported by an Australian Research Council Discovery project (DP 200100234). EP receives salary support from National Institutes of Health (K23MH112936). DLG has received research support from the NIH (NINDS, NIMH) and the DOD. He has received salary compensation through Cincinnati Children{\textquoteright}s for work as a clinical trial site investigator from Emalex (clinical trial, Tourette syndrome) and EryDel (clinical trial, ataxia telangiectasia). He has received book/publication royalties from Elsevier, Wolters Kluwer, and the Massachusetts Medical Society. He has received compensation for expert testimony for the US National Vaccine Injury Compensation Program, through the Department of Health and Human Services. He has received payment for medical expert opinions through Advanced Medical/Teladoc. He has served as a consultant for Applied Therapeutics and Eumentics Therapeutics. SHM has a US patent approved (Patent No: US10,410,041 B2) and his research is supported by grants from the NIH (NINDS, NIMH and NICHD) and NSF and from the Simons Foundation Autism Research Initiative and Waterloo Foundation. IL is supported by an individual EU fellowship (MSCA 798619). DAH has no disclosures. MG has no disclosures. Funding Information: JLH and NAP received salary support from the Nancy Lurie Marks foundation. RP and DP were supported through an Australian Government Research Training Program stipend. MRH was supported by the Australian Research Council (FT150100406, DP200101696). JPC is supported by an Australian Research Council Discovery project (DP 200100234). EP receives salary support from National Institutes of Health (K23MH112936). DLG has received research support from the NIH (NINDS, NIMH) and the DOD. He has received salary compensation through Cincinnati Children{\textquoteright}s for work as a clinical trial site investigator from Emalex (clinical trial, Tourette syndrome) and EryDel (clinical trial, ataxia telangiectasia). He has received book/publication royalties from Elsevier, Wolters Kluwer, and the Massachusetts Medical Society. He has received compensation for expert testimony for the US National Vaccine Injury Compensation Program, through the Department of Health and Human Services. He has received payment for medical expert opinions through Advanced Medical/Teladoc. He has served as a consultant for Applied Therapeutics and Eumentics Therapeutics. SHM has a US patent approved (Patent No: US10,410,041 B2) and his research is supported by grants from the NIH (NINDS, NIMH and NICHD) and NSF and from the Simons Foundation Autism Research Initiative and Waterloo Foundation. IL is supported by an individual EU fellowship (MSCA 798619). DAH has no disclosures. MG has no disclosures. Publisher Copyright: {\textcopyright} 2021, Crown.",

year = "2022",

month = jun,

doi = "10.3758/s13428-021-01680-9",

language = "English (US)",

volume = "54",

pages = "1530--1540",

journal = "Behavior Research Methods",

issn = "1554-351X",

publisher = "Springer New York",

number = "3",

}

TY - JOUR

T1 - OSARI, an Open-Source Anticipated Response Inhibition Task

AU - He, Jason L.

AU - Hirst, Rebecca J.

AU - Puri, Rohan

AU - Coxon, James

AU - Byblow, Winston

AU - Hinder, Mark

AU - Skippen, Patrick

AU - Matzke, Dora

AU - Heathcote, Andrew

AU - Wadsley, Corey G.

AU - Silk, Tim

AU - Hyde, Christian

AU - Parmar, Dinisha

AU - Pedapati, Ernest

AU - Gilbert, Donald L.

AU - Huddleston, David A.

AU - Mostofsky, Stewart

AU - Leunissen, Inge

AU - MacDonald, Hayley J.

AU - Chowdhury, Nahian S.

AU - Gretton, Matthew

AU - Nikitenko, Tess

AU - Zandbelt, Bram

AU - Strickland, Luke

AU - Puts, Nicolaas A.J.

N1 - Funding Information: JLH and NAP received salary support from the Nancy Lurie Marks foundation. RP and DP were supported through an Australian Government Research Training Program stipend. MRH was supported by the Australian Research Council (FT150100406, DP200101696). JPC is supported by an Australian Research Council Discovery project (DP 200100234). EP receives salary support from National Institutes of Health (K23MH112936). DLG has received research support from the NIH (NINDS, NIMH) and the DOD. He has received salary compensation through Cincinnati Children’s for work as a clinical trial site investigator from Emalex (clinical trial, Tourette syndrome) and EryDel (clinical trial, ataxia telangiectasia). He has received book/publication royalties from Elsevier, Wolters Kluwer, and the Massachusetts Medical Society. He has received compensation for expert testimony for the US National Vaccine Injury Compensation Program, through the Department of Health and Human Services. He has received payment for medical expert opinions through Advanced Medical/Teladoc. He has served as a consultant for Applied Therapeutics and Eumentics Therapeutics. SHM has a US patent approved (Patent No: US10,410,041 B2) and his research is supported by grants from the NIH (NINDS, NIMH and NICHD) and NSF and from the Simons Foundation Autism Research Initiative and Waterloo Foundation. IL is supported by an individual EU fellowship (MSCA 798619). DAH has no disclosures. MG has no disclosures. Funding Information: JLH and NAP received salary support from the Nancy Lurie Marks foundation. RP and DP were supported through an Australian Government Research Training Program stipend. MRH was supported by the Australian Research Council (FT150100406, DP200101696). JPC is supported by an Australian Research Council Discovery project (DP 200100234). EP receives salary support from National Institutes of Health (K23MH112936). DLG has received research support from the NIH (NINDS, NIMH) and the DOD. He has received salary compensation through Cincinnati Children’s for work as a clinical trial site investigator from Emalex (clinical trial, Tourette syndrome) and EryDel (clinical trial, ataxia telangiectasia). He has received book/publication royalties from Elsevier, Wolters Kluwer, and the Massachusetts Medical Society. He has received compensation for expert testimony for the US National Vaccine Injury Compensation Program, through the Department of Health and Human Services. He has received payment for medical expert opinions through Advanced Medical/Teladoc. He has served as a consultant for Applied Therapeutics and Eumentics Therapeutics. SHM has a US patent approved (Patent No: US10,410,041 B2) and his research is supported by grants from the NIH (NINDS, NIMH and NICHD) and NSF and from the Simons Foundation Autism Research Initiative and Waterloo Foundation. IL is supported by an individual EU fellowship (MSCA 798619). DAH has no disclosures. MG has no disclosures. Publisher Copyright: © 2021, Crown.

PY - 2022/6

Y1 - 2022/6

N2 - The stop-signal paradigm has become ubiquitous in investigations of inhibitory control. Tasks inspired by the paradigm, referred to as stop-signal tasks, require participants to make responses on go trials and to inhibit those responses when presented with a stop-signal on stop trials. Currently, the most popular version of the stop-signal task is the ‘choice-reaction’ variant, where participants make choice responses, but must inhibit those responses when presented with a stop-signal. An alternative to the choice-reaction variant of the stop-signal task is the ‘anticipated response inhibition’ task. In anticipated response inhibition tasks, participants are required to make a planned response that coincides with a predictably timed event (such as lifting a finger from a computer key to stop a filling bar at a predefined target). Anticipated response inhibition tasks have some advantages over the more traditional choice-reaction stop-signal tasks and are becoming increasingly popular. However, currently, there are no openly available versions of the anticipated response inhibition task, limiting potential uptake. Here, we present an open-source, free, and ready-to-use version of the anticipated response inhibition task, which we refer to as the OSARI (the Open-Source Anticipated Response Inhibition) task.

AB - The stop-signal paradigm has become ubiquitous in investigations of inhibitory control. Tasks inspired by the paradigm, referred to as stop-signal tasks, require participants to make responses on go trials and to inhibit those responses when presented with a stop-signal on stop trials. Currently, the most popular version of the stop-signal task is the ‘choice-reaction’ variant, where participants make choice responses, but must inhibit those responses when presented with a stop-signal. An alternative to the choice-reaction variant of the stop-signal task is the ‘anticipated response inhibition’ task. In anticipated response inhibition tasks, participants are required to make a planned response that coincides with a predictably timed event (such as lifting a finger from a computer key to stop a filling bar at a predefined target). Anticipated response inhibition tasks have some advantages over the more traditional choice-reaction stop-signal tasks and are becoming increasingly popular. However, currently, there are no openly available versions of the anticipated response inhibition task, limiting potential uptake. Here, we present an open-source, free, and ready-to-use version of the anticipated response inhibition task, which we refer to as the OSARI (the Open-Source Anticipated Response Inhibition) task.

KW - Behavioral Inhibition

KW - Inhibition

KW - Stopping

KW - anticipation

KW - executive functioning

KW - opensource

KW - stop-signal task

UR - http://www.scopus.com/inward/record.url?scp=85118638651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85118638651&partnerID=8YFLogxK

U2 - 10.3758/s13428-021-01680-9

DO - 10.3758/s13428-021-01680-9

M3 - Article

C2 - 34751923

AN - SCOPUS:85118638651

VL - 54

SP - 1530

EP - 1540

JO - Behavior Research Methods

JF - Behavior Research Methods

SN - 1554-351X

IS - 3

ER -

OSARI, an Open-Source Anticipated Response Inhibition Task

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this